ArticleBiomedical optics express2022
Cell-modified plasmonic interface for the signal-amplified detection of Cucurbitacin E.
Article in Biomedical optics express, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Introduction to the feature issue: Advances in Optical Biosensors for Biomedical Applications.Biomedical optics express · 2024Article
- Review
- Biological Cells as Natural Biophotonic Devices: Fundamental and Applications-introduction to the feature issue.Biomedical optics express · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cucurbitacin E (CuE) plays an important role in anticancer, antichemical carcinogenesis, and body immunity, etc., and the detection of its concentration is meaningful to pharmacological studies and clinical applications. However, the small molecular weight of CuE makes direct detection difficult through a surface plasmon resonance (SPR) sensor. In this work, we propose a cells-amplified signal strategy at the plasmonic interface, realizing the detection of CuE with ultra-low concentration. The seeded HeLa cells are modified onto the surface of the SPR sensor, and a small amount of CuE can lead to the remarkable morphology change of cells and the release of cell-related substances onto the plamonic interface, thus significantly amplifying the signal. Experimental results show that by using an unmodified SPR sensor with the bulk refractive index sensitivity of 2367.3 nm/RIU (RIU: refractive index unit), there no effective signal can be detected during the CuE concentration range of 0-100 nM; whereas, employing the proposed strategy, the signal for CuE detection can be significantly enhanced, resulting in a high detection sensitivity of 0.6196 nm/nM, corresponding to a limit of detection of 45.2 pM (25.2 pg/mL). The proposed cells-based signal amplifying strategy shows great potential applications in drug screening or bio-sensing to small molecules with low concentration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.